Zentek Ltd. · TSXV:ZEN
Zentek — Investor Presentation (February 2022)
23 slides from Zentek's investor presentation, Feb 16, 2022
Slide 1: Corporate Presentation
TSXV: ZEN Corporate Presentation OTCQB: ZENYF
Slide 2: Disclaimers
Disclaimers This presentation is being provided for information purposes only and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of Zentek Ltd. (“Zentek” or the “Company”
Slide 3: Who We Are
Who We Are Zentek is a Canadian, IP development and commercialization company focused on next- gen healthcare solutions in the areas of prevention, detection and treatment. 3
Slide 4: Common Share Listings
Common Share Listings TSXV: ZEN ZENYF ZEN OTCQB: ZENYF Exchange OTCQB TSXV Recent Price $2.98 C$3.77 (a/o 2/15/22) (a/o 2/15/22) • ~US$300M market capitalization 52 Wk. Range $1.36 - $5.95 C$1.71-C$7.50 (no debt) Market Cap $297M (a/o 2/15/22) C$373M (a/o 2/15/22) • Completed capital raise of C$33M
Slide 5: Corporate Overview
Corporate Overview IP development and commercialization company focused on next-gen, nanotechnology-enabled healthcare solutions Robust IP development pipeline with near-term commercialization opportunities: PREVENTION DETECTION ZenGUARDTM for PPE and Aptamer-based rapid detection for potentially ot
Slide 6: Prevention
PREVENTION ZENGUARD.
Slide 7: ZenGUARD Technology
ZenGUARD Technology TM Typical ASTM Level 3, Antimicrobial Coating 3-ply Surgical Mask Seasonal Flu VS Tuberculosis SARS-CoV-2 • Patent pending, non-toxic, antimicrobial coating that has shown to be 99+% effective deactivating numerous pathogens, including SARS-CoV-2 • BFE/VFE > 99.99%1: 98.9% more
Slide 8: ZenGUARD – Next-Gen Front-Line Protection
ZenGUARD – Next-Gen Front-Line Protection TM Antimicrobial Coating ZenGUARDTM on masks, and potentially on other PPE to help protect frontline workers and the public and to reduce the spread of pathogens (including and beyond COVID-19) Health Canada • Health Canada has authorized the sale of ZenGUAR
Slide 9: Monetizing Current Opportunities – Prevention
Monetizing Current Opportunities – Prevention Health Canada Authorized Antimicrobial Coating > US $52B 1 > US $66B 2 Personal Protective Equipment Indoor Air Quality (PPE) ZenGUARDTM on masks, and potentially ZenGUARDTM potentially used on gloves and other PPE to help protect air filters to kill air
Slide 10: Disposable Mask Market Opportunity
Disposable Mask Market Opportunity Assumptions: Market Penetration and • 1.5 trillion masks being used globally per Gross Margin Scenario Analysis year 1 (For Illustrative Purposes Only2) • We believe steady state demand could be ~60% of current need or ~930 billion $1,000 279 372 464 557 186 232 •
Slide 11: ZenGUARD for PPE & Indoor Air Quality Markets
ZenGUARD for PPE & Indoor Air Quality Markets TM Commercialization & Production • Partnered with Trebor Rx for masks/filters with ZenGUARD™; initial delivery of and revenue generated in Q3 of 2021 • Received a medical device establishment license (MDEL) from Health Canada, permitting Zentek to manuf
Slide 12: Detection
- ; Vj < 4G Vv » Vp y DETEGHON
Slide 13: Aptamer-Based Technology
Aptamer-Based Technology HIV E Coli Strep Throat Disease Detection Platform Seasonal Flu Our simple and fast technology can potentially detect Other Cancer Aptamer numerous pathogens to: Can be customized • Identify infections sooner Cells to attach to and Tuberculosis • Potentially end outbreaks de
Slide 14: Aptamer-Based Rapid Detection Overview
Aptamer-Based Rapid Detection Overview Our Aptamer-Based Rapid Technology is: SIMPLE FAST ACCURATE SCALABLE AFFORDABLE Saliva-based tests are Test results provided Impedance-based Aptamers are Simple, low-cost easier to use with less in 7-10 minutes detection enables synthetic molecules hardware and
Slide 15: Rapid Detection Current and Future Demand
Rapid Detection Current and Future Demand • Pandemic highlights the importance of rapid, accurate >2.6B testing $23.4B COVID Tests • Simple, low-cost options and familiarity anticipated to 2020 Global Rapid Test Kit Administered Globally1 make testing even more widespread further supporting Market E
Slide 16: Rapid Detection Commercialization
Rapid Detection Commercialization Strategic Partners neoaptamers neoventures biotechnology inc. Milestones • Three-buffer methodology reduced to a two-buffer approach to simplify user experience • Aptamer with higher binding affinity developed for COVID-19 Focus Areas • Model to further improve dete
Slide 17: Summary
Summary Zentek develops and commercializes IP for next-gen, nanotechnology-enabled healthcare solutions Robust IP pipeline with large-scale, high-growth commercialization opportunities PREVENTION DETECTION IP PIPELINE • Building on Health Canada • Additional testing for • Continuing to develop high-
Slide 18: Contact Page
Contact Page FOR ALL INQUIRIES PLEASE CONTACT: Matt Blazei CoreIR [email protected] Ryan Shacklock Zentek [email protected] 1205 Amber Drive, Suite 210 Thunder Bay, Ontario P7B 6M4 Canada w w w.zentek.com 18
Slide 19: Appendix
APPENDIX 19
Slide 20: Potential Therapeutic Treatment
Potential Therapeutic Treatment In Vitro Efficacy • Our patent pending compound has shown 99.9% effectiveness against Gram + and Gram – bacteria, including antimicrobial resistant (AMR) organisms and fungi Safety • Cytotoxicity testing results recorded no adverse effects on lab animals after seven d
Slide 21: Growing IP Pipeline Focused on Sustainable Development
Growing IP Pipeline Focused on Sustainable Development Clean Advanced Tech Materials Graphene-Based Fuel Additive Carbon-Based Icephobic Coating • Stable additive that has shown to • Has shown to be a 96% improvement increase the fuel economy of over aluminum and 80% diesel combustion by up to 10% i
Slide 22: Leadership – Officers/Directors
Leadership – Officers/Directors Greg Fenton - Chief Executive Officer, Director Seasoned investment professional, with a Bay Street career spanning nearly 30 years. He has worked in various capacities with ever-increasing responsibility in both the Canadian banking and investment management sectors.
Slide 23: Advisory Board
Advisory Board Dr. Yingfu Li - Professor in the Department of Biochemistry and Biomedical Sciences Dr. Li is a Professor in the Department of Biochemistry and Biomedical Sciences at McMaster University. He earned a Ph.D. in Biochemistry from Simon Fraser University, where he discovered a DNA molecul